Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANVS Annovis Bio	$2.61 -3.3%	$2.04	$1.11 ▼ $17.88	$50.91M	1.61	741,257 shs	371,126 shs
AQST Aquestive Therapeutics	$3.25 -4.4%	$2.85	$2.12 ▼ $5.80	$322.82M	1.94	1.54 million shs	1.68 million shs
ATOS Atossa Genetics	$0.79 -1.6%	$0.82	$0.55 ▼ $1.66	$102.04M	0.93	772,505 shs	723,543 shs
GLYC GlycoMimetics	$0.16 -6.6%	$20.62	$14.06 ▼ $63.00	$10.00M	1.62	69,301 shs	1.05 million shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANVS Annovis Bio	0.00%	-7.21%	+31.26%	+44.31%	-56.03%
AQST Aquestive Therapeutics	0.00%	-4.97%	+38.30%	0.00%	+26.95%
ATOS Atossa Genetics	0.00%	-4.88%	-5.01%	+5.33%	-30.09%
GLYC GlycoMimetics	0.00%	-1.27%	-99.37%	-99.41%	-99.40%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ANVS Annovis Bio	2.3741 of 5 stars	3.5	1.0	0.0	3.4	1.7	0.6
AQST Aquestive Therapeutics	1.4027 of 5 stars	3.5	1.0	0.0	2.8	0.0	0.0
ATOS Atossa Genetics	1.1531 of 5 stars	3.7	0.0	0.0	0.6	1.7	0.0
GLYC GlycoMimetics	1.1202 of 5 stars	0.0	3.0	4.6	1.1	1.7	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANVS Annovis Bio	3.00	Buy	$30.25	1,058.12% Upside
AQST Aquestive Therapeutics	3.00	Buy	$10.14	212.09% Upside
ATOS Atossa Genetics	3.33	Buy	$6.17	680.59% Upside
GLYC GlycoMimetics	2.50	Moderate Buy	N/A	N/A

Current Analyst Ratings Breakdown

Latest GLYC, ANVS, AQST, and ATOS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/9/2025	ANVS Annovis Bio	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$30.00 ➝ $12.00
6/6/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.25 ➝ $7.50
6/5/2025	ATOS Atossa Genetics	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$4.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/15/2025	ANVS Annovis Bio	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$26.00 ➝ $17.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
4/21/2025	ATOS Atossa Genetics	Ascendiant Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$7.00 ➝ $7.25
4/2/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
3/26/2025	ATOS Atossa Genetics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00

(Data available from 6/23/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANVS Annovis Bio	N/A	N/A	N/A	N/A	$0.67 per share	N/A
AQST Aquestive Therapeutics	$57.56M	5.61	N/A	N/A	($0.66) per share	-4.92
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	$0.57 per share	N/A
GLYC GlycoMimetics	$10K	1,000.25	N/A	N/A	$0.08 per share	1.94

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANVS Annovis Bio	-$24.59M	-$2.16	N/A	N/A	N/A	N/A	-300.56%	-193.50%	8/13/2025 (Estimated)
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
ATOS Atossa Genetics	-$25.50M	-$0.21	N/A	N/A	N/A	N/A	-33.90%	-31.53%	8/11/2025 (Estimated)
GLYC GlycoMimetics	-$37.88M	-$0.46	N/A	N/A	N/A	N/A	-230.74%	-177.39%	8/6/2025 (Estimated)

Latest GLYC, ANVS, AQST, and ATOS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	GLYC GlycoMimetics	-$5.00	-$4.00	+$1.00	-$0.04	N/A	N/A
5/13/2025	Q1 2025	ANVS Annovis Bio	-$0.47	-$0.32	+$0.15	-$0.32	N/A	N/A
5/13/2025	Q1 2025	ATOS Atossa Genetics	-$0.06	-$0.05	+$0.01	-$0.05	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
3/25/2025	Q4 2024	ATOS Atossa Genetics	-$0.0633	-$0.05	+$0.0133	-$0.05	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANVS Annovis Bio	N/A	N/A	N/A	N/A	N/A
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
ATOS Atossa Genetics	N/A	N/A	N/A	N/A	N/A
GLYC GlycoMimetics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANVS Annovis Bio	N/A	10.68	10.68
AQST Aquestive Therapeutics	N/A	4.87	4.48
ATOS Atossa Genetics	N/A	12.67	12.67
GLYC GlycoMimetics	N/A	1.92	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANVS Annovis Bio	15.83%
AQST Aquestive Therapeutics	32.45%
ATOS Atossa Genetics	12.74%
GLYC GlycoMimetics	75.19%

Insider Ownership

Company	Insider Ownership
ANVS Annovis Bio	20.80%
AQST Aquestive Therapeutics	7.85%
ATOS Atossa Genetics	8.70%
GLYC GlycoMimetics	8.70%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANVS Annovis Bio	3	19.49 million	15.43 million	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
ATOS Atossa Genetics	8	129.17 million	117.93 million	Optionable
GLYC GlycoMimetics	50	64.53 million	58.90 million	Optionable

GLYC, ANVS, AQST, and ATOS Headlines

Recent News About These Companies

LifeSci Capital Initiates Coverage of GlycoMimetics (CBIO) with Outperform Recommendation

June 20 at 5:47 AM | msn.com

GlycoMimetics (NASDAQ:GLYC) Stock Price Crosses Below 200 Day Moving Average - Should You Sell?

June 20 at 4:11 AM | americanbankingnews.com

GlycoMimetics trading halted, news pending

June 14, 2025 | msn.com

GlycoMimetics announces 1-for-100 reverse stock split

June 7, 2025 | investing.com

GlycoMimetics Stockholders Approve Proposed Merger with Crescent Biopharma and All Related Proposals

June 5, 2025 | businesswire.com

Crescent Biopharma to Present at the Jefferies Global Healthcare Conference

May 29, 2025 | globenewswire.com

GLYCOMIMETICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of GlycoMimetics, Inc. - GLYC

May 16, 2025 | businesswire.com

$HAREHOLDER ALERT: The M&A Class Action Firm Continues To Investigate The Merger – GLYC,

May 7, 2025 | bakersfield.com

Crescent Biopharma Appoints David Lubner to Board of Directors

April 28, 2025 | globenewswire.com

GlycoMimetics Stock Short Interest Report | NASDAQ:GLYC | Benzinga

April 18, 2025 | benzinga.com

Crescent moon shot to scale the Summit in VEGFxPD-1

April 5, 2025 | bioworld.com

Crescent Biopharma Appoints Joshua Brumm as Chief Executive Officer and Expands Leadership Team to Advance Pipeline of Potentially Best-in-Class Oncology Therapeutics

April 3, 2025 | globenewswire.com

Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation

March 22, 2025 | msn.com

Cantor Fitzgerald Initiates Coverage of GlycoMimetics (GLYC) with Overweight Recommendation

March 22, 2025 | msn.com

Crescent Biopharma initiated with an Overweight at Cantor Fitzgerald

March 22, 2025 | markets.businessinsider.com

Acute Myeloid Leukemia Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies

March 7, 2025 | theglobeandmail.com

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CMRX and GLYC on Behalf of Shareholders

March 5, 2025 | prnewswire.com

Crescent Biopharma to Present at the TD Cowen 45th Annual Health Care Conference

February 26, 2025 | globenewswire.com

US Penny Stocks To Watch In February 2025

February 20, 2025 | finance.yahoo.com

Top 5 Biotech Stocks That Got Most Retail Buzz Last Week

February 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GLYC, ANVS, AQST, and ATOS Company Descriptions

Annovis Bio NYSE:ANVS

$2.61 -0.09 (-3.26%)

Closing price 06/20/2025 03:59 PM Eastern

Extended Trading

$2.73 +0.12 (+4.52%)

As of 06/20/2025 07:44 PM Eastern

Annovis Bio, Inc., a clinical stage drug platform company, develops drugs to treat neurodegeneration. The company's lead product candidate is Buntanetap, which has completed three Phase 1/2 clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, and other chronic neurodegenerative diseases. It is also developing ANVS405, which is in Phase 2 and Phase 3 efficacy studies, an intravenous drug for protecting the brain after traumatic brain injury and/or stroke; and ANVS301, which is in Phase I clinical trials, an orally administered drug to increase cognitive capability in later stages of AD and dementia. The company was incorporated in 2008 and is based in Malvern, Pennsylvania.

Aquestive Therapeutics NASDAQ:AQST

$3.25 -0.15 (-4.41%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$3.26 +0.02 (+0.46%)

As of 06/20/2025 07:56 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

Atossa Genetics NASDAQ:ATOS

$0.79 -0.01 (-1.64%)

Closing price 06/20/2025 04:00 PM Eastern

Extended Trading

$0.81 +0.02 (+3.04%)

As of 06/20/2025 07:57 PM Eastern

Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.

GlycoMimetics NASDAQ:GLYC

$0.16 -0.01 (-6.63%)

Closing price 06/13/2025

Extended Trading

$0.16 0.00 (0.00%)

As of 06/13/2025 07:49 PM Eastern

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time